



Biotech Daily

Monday June 6, 2016

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: BIONOMICS UP 10%; ANTISENSE DOWN 10%**
- * **DIMERIX DOSES 11th OF 30 DMX-200 KIDNEY DISEASE PATIENTS**
- * **AIRXPANDERS REQUESTS 'CAPITAL RAISING' TRADING HALT**
- * **TORONTO'S SPROTT, W WHITNEY GEORGE TAKE 5% OF RHINOMED**
- * **SOMNOMED CHAIRMAN DR PETER NEUSTADT HOLDS 7%**
- * **RAVINDRAN KRISHNAN TAKES 6.5% OF MACH7**
- * **NUHEARA CHAIR GRANT MOONEY GOES, JUSTIN MILLER INTERIM; HALT**
- * **SCIGEN CHAIR DR SLAWOMIR ZIEGERT GOES, DR JAMES KIM CEO**

MARKET REPORT

The Australian stock market was up 0.78 percent on Monday June 6, 2016 with the ASX200 up 41.5 points to 5,360.4 points.

Ten of the Biotech Daily Top 40 stocks were up, 16 fell, nine traded unchanged and five were untraded.

Bionomics was the best, up three cents or 10 percent to 33 cents, with 520,755 shares traded.

Universal Biosensors climbed 5.6 percent; Osprey was up 4.35 percent; Acrux, Factor Therapeutics, Orthocell and Viralytics rose more than two percent; Clinuvel and Pharmaxis were up more than one percent; with Cochlear and CSL up by less than one percent.

Antisense led the falls, down 0.4 cents or 10 percent to 3.6 cents with 27,450 shares traded.

Oncosil lost 9.1 percent; Prana fell 7.95 percent; Biotron was down 4.4 percent; Cellmid was down 3.7 percent; Anteo, Ellex and Prima shed two percent or more; Actinogen, Admedus, Impedimed, Neuren, Reva and Sirtex were down one percent or more; with Medical Developments, Pro Medicus and Resmed down by less than one percent.

DIMERIX

Dimerix says that with 11 of 30 patients dosed in its phase II trial of DMX-200 for chronic kidney disease it expects to report interim data by October 2016.

Dimerix executive chairman Dr James Williams said that “the milestone of dosing 10 patients is an important one, as it should enable interim information to be elucidated under the trial”.

“It confirms we are meeting the recruitment targets and timelines previously communicated to the market,” Dr Williams said.

Dimerix said that DMX-200 combined two existing drugs, the anti-inflammatory chemokine receptor CCR2 blocker propagermanium and an angiotensin II type I receptor blocker irbesartan which was registered in the US for hypertension and treatment of diabetic nephropathy in certain patients.

The company said that the first part of the phase II open-label trial aimed to recruit up to 30 patients at four sites in Melbourne to demonstrate safety and the reduction of proteinuria in patients with chronic kidney disease.

Dimerix said that proteinuria was common in chronic kidney disease patients and was a strong independent risk factor for disease progression.

The company said that reducing proteinuria reduced the risk of chronic kidney disease progression and its consequences of progressive loss of renal function leading to renal failure and the development and progression of cardiovascular disease.

Dimerix said that patients in the study previously were prescribed irbesartan and as part of the trial protocol began a dose of 30mg a day of propagermanium.

The company said that the investigators reviewed the patients at four week intervals, escalating the dose to 60mg, 90mg, 150mg and 240mg a day over each four week period.

Dimerix said that the supply of propagermanium to patients following their participation in the trial could be approved under the Australian Therapeutic Goods Administration special access scheme.

The company said that the first patient to complete the DMX-200 phase II trial was continuing to access propagermanium under the scheme.

Dimerix was up 0.1 cents or 14.3 percent to 0.8 cents with 4.5 million shares traded.

AIRXPANDERS

Airxpanders has requested a trading halt “pending an announcement ... in relation to a proposed capital raising”.

Trading will resume on June 8, 2016 or on an earlier announcement.

Airxpanders last traded at 89 cents.

RHINOMED

The Calrsbad, California-based W Whitney George says he has become a substantial shareholder in Rhinomed with the acquisition of 43,566,205 shares (5.35%).

The substantial shareholder notice said that Mr George acquired shares between May 9 and June 3, 2016 at prices ranging from one cent a share to 2.2 cents a share.

The notice said that W Whitney George was associated with the Toronto, Ontario-based Sprott Asset Management, whose website said he was the senior portfolio manager of the Sprott Focus Trust.

Rhinomed was unchanged at 2.2 cents with two million shares traded.

SOMNOMED

Somnomed executive chairman Dr Peter Neustadt says he has increased his holding from 3,702,0123 shares (7.293%) to 4,106,705 shares (7.24%).

Dr Neustadt's substantial shareholder notice said that the shares were acquired through the Bellevue Hill, Sydney-based Belgove Pty Ltd and P Neustadt Holdings Pty Ltd.

Dr Neustadt said that he acquired 279,682 shares at \$2.50 a share in the recent rights offer and exercised 125,000 options for \$108,750 or 87 cents each.

Last week, Somnomed said its retail rights offer raised \$6,468,280 at \$2.50 a share, taking the total raised to \$10,503,238 (BD: Jun 1, 2016).

In May, Somnomed said its under-written, two-for-25, institutional entitlement offer raised \$4,034,958 at the same price (BD: May 5, 2016).

Somnomed was up 12 cents or 3.7 percent to \$3.35.

MACH7 TECHNOLOGIES (FORMERLY 3D MEDICAL)

The Singapore-based Ravindran Krishnan says he has become substantial in Mach7 with the acquisition of 57,805,614 shares (6.46%).

Mr Krishnan's substantial shareholder notice said the shares were acquired on April 8, 2016 as consideration for the acquisition of Mach7 Technologies Pte Ltd at a deemed price of 10 cents a share.

Mach7 was unchanged at five cents.

NUHEARA

Nuheara says that chairman and company secretary Grant Mooney has resigned effective from June 4, 2016.

Nuheara said that managing director and chief executive officer Justin Miller had been appointed interim executive chairman with Susan Hunter appointed company secretary.

The company said that it was undertaking "a global search" for a new chairman.

Nuheara said that Ms Hunter had more than 22 years' experience in the corporate finance industry, was the founder and managing director of consulting firm Hunter Corporate and previously held management roles at Ernst & Young, Pricewaterhousecoopers and Bankwest.

The company said that Ms Hunter held a Bachelor of Commerce and had experience as a company secretary and non-executive director with companies listed on the ASX, Toronto Stock Exchange and London's Alternative Investment Market.

Nuheara said it was beginning a search for directors and leaders to deliver its sound filtering and device Iqubuds.

Nuheara requested a trading halt to June 8, 2016 "pending the release of an announcement regarding the company's contractual selection of a contract manufacturer" and last traded at 9.1 cents.

SCIGEN

Scigen says that chairman, chief executive officer Dr Slawomir Ziegert resigned on June 1, 2016 and has resigned as president of 95.57 percent owner Bioton SA.

The Singapore-based and ASX-listed Scigen said that Dr Ziegert will join the Warsaw, Poland-based Bioton's supervisory board.

The company said that business development director Dr James Kim, who was appointed to that position on April 18, 2016, had been appointed chief executive officer from June 1, 2016.

Scigen said that Dr Kim's employment agreement with Bioton allowed him "to hold any key position within the Bioton group companies, including Scigen, as deemed necessary".

The company said it would not pay Dr Kim any remuneration, but he would be "responsible for developing and implementing new strategic initiatives, managing the overall operations and resources of the company and acting as the main point of communication between the board of directors and the management of the company.

Scigen said that Dr James Kim held a degree from Trinity International University, Illinois and held a Doctorate of Philosophy in biochemistry from the University of Wisconsin-Madison.

The company said that Dr Kim worked with LG Life Sciences in corporate business development, diagnostics strategy and planning and business strategy for pharmaceuticals, biologicals and in-vitro diagnostics.

Between 2009 and 2011 he worked for the South Korea-based Bioneer Corp as team leader for molecular diagnostics technical support and senior scientist and manager for the development of molecular diagnostics-based service platforms.

In its ASX profile Scigen described itself as "a bio-pharmaceutical company engaged in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare ... in the areas of gastroenterology, endocrinology and immunology. Scigen was untraded at one cent.